Hepatitis B and pregnancy. Part 1. Thirteen practical issues in antenatal period;Hépatite B et grossesse. Partie 1. Treize questions pratiques en période anténatale

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 45, Issue 6, 2016, Pages 531-539

  Fouquet, A ^a   Jambon, A C ^b   Canva, V ^a   Bocket Mouton, L ^a   Gottrand, F ^a   Subtil, D ^a,c  

^a UNIV LILLE   (France)

^b CENTRE HOSPITALIER DE TOURCOING   (France)

^c UNIV LILLE   (France)

Author keywords

Amniocentesis; Antiviral treatment; Hepatitis B; Maternal fetal transmission; Pregnancy; Prevention; Serovaccination

Indexed keywords

LAMIVUDINE; TENOFOVIR;

AMNIOCENTESIS; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; FEMALE; GESTURE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PREGNANCY; PRENATAL PERIOD; VIRUS LOAD; VIRUS TRANSMISSION; ADULT; FRANCE; HEPATITIS B, CHRONIC; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ADULT; FEMALE; FRANCE; HEPATITIS B, CHRONIC; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84960839750     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: 10.1016/j.jgyn.2016.02.004     Document Type: Review

References (50)

1. OMS. Hépatite B-principaux repères. Aide mémoire no204;2014 [Available from: http://www. who. int/mediacentre/factsheets/fs204/fr/].
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. Gastroen-terology 2004;127:S35-50 [Epub 2004/10/28].
3. Bhat P, Anderson DA. Hepatitis B virus translocates across atrophoblastic barrier. J Virol 2007;81:7200-7.
4. Bernard PH. Sérologie des hépatites B et C : interprétation etconséquences pratiques chez la femme [Hepatitis B and C viro-logical tests: interpretation and practical results in women]. Gynecol Obstet Fertil 2005;33:423-8.
5. Chang MH. Hepatitis B virus infection. Semin Fetal NeonatalMed 2007;12:160-7.
6. Meffre C. Prévalence des hépatites B et C en France en 2004. Saint Maurice: Institut de veille sanitaire; 2006 [176p].
7. Denis FBP, Chastagner M, Delpeyroux C. Dépistage de l'AgHBschez les femmes enceintes : quel taux de couverture ? Enquêteen Haute-Vienne. BEH 2003;33:157-8.
8. France adCSdHd. Décret du 14 février 1992 relatif aux examensobligatoires, prénuptial, pré-et postnatal, circulaire de laDirection Générale de la Santé 2004-534; 2006.
9. Braillon A, Nguyen-Khac E, Merlin J, Dubois G, Gondry J, CapronD. Grossesse et hépatite B en Picardie : traçabililité du dépis-tage et prévalence [HBsAg screening during pregnancy in theFrench province Picardy]. Gynecol Obstet Fertil 2010;38:13-7.
10. Nadler JP. Multiple sclerosis and hepatitis B vaccination. ClinInfect Dis 1993;17:928-9.
11. Herroelen L, de Keyser J, Ebinger G. Central nervous systemdemyelination after immunisation with recombinant hepatitisB vaccine. Lancet 1991;338:1174-5.
12. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis Bvaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004;63:838-42.
13. Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S. HepatitisB vaccine and risk of relapse after a first childhood episode ofCNS inflammatory demyelination. Brain 2007;130:1105-10.
14. Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepa-titis B vaccination and the risk of childhood-onset multiplesclerosis. Arch Pediatr Adolesc Med 2007;161:1176-82.
15. Martinot A. Vaccinoscopie : étude de l'évolution annuelleentre 2008 et 2011 de la couverture vaccinale des enfants demoins de 7 ans dans la population française. Arch Pediatr2013;20:837-44.
16. Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-CarrieN, et al. Characteristics of patients with chronic hepatitis B inFrance: predominant frequency of HBe antigen negative cases. J Hepatol 2006;45:355-60 [Epub 2006/06/06].
17. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G,Tanzi E, et al. Vaccine-induced escape mutant of hepatitis Bvirus. Lancet 1990;336:325-9.
18. Liu SL, Dong Y, Zhang L, Li MW, Wo JE, Lu LW, et al. Influenceof HBV gene heterogeneity on the failure of immunizationwith HBV vaccines in eastern China. Arch Virol 2009;154:437-43.
19. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis Bimmunisation in newborn infants of mothers positive for hepa-titis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.
20. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG,et al. Perinatal transmission of hepatitis B virus: an Australianexperience. Med J Australia 2009;190:489-92.
21. Elefsiniotis IS, Papadakis M, Vlachos G, Vezali E, Tsoumakas K,Saroglou G, et al. Presence of HBV-DNA in cord blood is associa-ted with spontaneous preterm birth in pregnant women withHBeAg-negative chronic hepatitis B virus infection. Interviro-logy 2011;54:300-4.
22. Deng L, Li X, Shi Z, Jiang P, Chen D, Ma L. Maternal and perinataloutcome in cases of fulminant viral hepatitis in late pregnancy. Int J Gynaecol Obstet 2012;119:145-8.
23. Wong S, Chan LY, Yu V, Ho L. Hepatitis B carrier andperinatal outcome in singleton pregnancy. Am J Perinatol1999;16:485-8.
24. Safir A, Levy A, Sikuler E, Sheiner E. Maternal hepatitis B virusor hepatitis C virus carrier status as an independent risk factorfor adverse perinatal outcome. Liver Int 2010;30:765-70.
25. Elefsiniotis I, Tsoumakas K, Vezali E, Glynou I, DrakoulisN, Saroglou G. Spontaneous preterm birth in women withchronic hepatitis B virus infection. Int J Gynaecol Obstet2010;110:241-4.
26. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrierstatus on pregnancy outcomes: a case-control study. J Hepatol2005;43:771-5.
27. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepa-titis B infection and gestational diabetes mellitus. J Hepatol2007;47:46-50.
28. Bongain. Hépatite B et grossesse. CNGOF; 1995.
29. Ducarme G, Ceccaldi PF, Bernuau J, Luton D. Amniocentèse etrisque viral (hépatites virales B, C et VIH) [Amniocentesis andviral risk (hepatitis B, C virus and HIV)]. J Gynecol Obstet BiolReprod 2009;38:469-73.
30. Gianlordino. Blood contamination of amniotic fluid afteramniocentesis in relation to placental location. Prenat Diagn1996;16:180-2.
31. Nuss S, Brebaum D, Grond-Ginsbach C. Maternal cell conta-mination in amniotic fluid samples as a consequence of thesampling technique. Hum Genet 1994;93:121-4.
32. Grosheide PM, Quartero HW, Schalm SW, Heijtink RA, Chris-tiaens GC. Early invasive prenatal diagnosis in HBsAg-positivewomen. Prenat Diagn 1994;14:553-8.
33. Alexander JM, Ramus R, Jackson G, Sercely B, Wendel Jr GD. Risk of hepatitis B transmission after amniocentesis in chronichepatitis B carriers. Infect Dis Obstet Gynecol 1999;7:283-6.
34. Towers CV, Asrat T, Rumney P. The presence of hepatitis B sur-face antigen and deoxyribonucleic acid in amniotic fluid andcord blood. Am J Obstet Gynecol 2001;184:1514-8 [discussion8-20].
35. Davies G, Wilson RD, Desilets V, Reid GJ, Shaw D, SummersA, et al. Amniocentesis and women with hepatitis B, hepatitisC, or human immunodeficiency virus. J Obstet Gynaecol Can2003;25:145-8 [9-52].
36. Lopez M, Coll O. Chronic viral infections and invasiveprocedures: risk of vertical transmission and current recom-mendations. Fetal Diagn Ther 2010;28:1-8.
37. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surfaceantigenemia at birth: a long-term follow-up study. J Pediatr1998;133:374-7.
38. Lin HH, Lee TY, Chen DS, Sung JL, Ohto H, Etoh T, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection withhepatitis B virus. J Pediatr 1987;111:877-81.
39. Han GR, Xu CL, Zhao W, Yang YF. Management of chronic hepa-titis B in pregnancy. World J Gastroenterol 2012;18:4517-21[Epub 2012/09/13].
40. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, et al. Theeffects of telbivudine in late pregnancy to prevent intrauterinetransmission of the hepatitis B virus: a systematic review andmeta-analysis. Virol J 2012;9:185.
41. Brown Jr RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, LeuCS, et al. Hepatitis B virus and human immunodeficiency virusdrugs in pregnancy: findings from the Antiretroviral PregnancyRegistry. J Hepatol 2012;57:953-9.
42. http://www.apregistry.com.
43. Liver EAftsot. EASL clinical practice guidelines: management ofchronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
44. Patel D, Thorne C, Fiore S, Newell ML. Does highly activeantiretroviral therapy increase the risk of congenital abnor-malities in HIV-infected women? J Acquire Immune Defic Syndr2005;40:116-8 [Epub 2005/08/27].
45. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Too-key PA. Antiretroviral therapy and congenital abnormalitiesin infants born to HIV-infected women in the UK and Ireland,1990-2007. AIDS 2009;23:519-24 [Epub 2009/01/24].
46. Bzowej NH. Hepatitis B Therapy in pregnancy. Curr Hepat Rep2010;9:197-204 [Epub 2010/10/16].
47. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lami-vudine in late pregnancy to prevent perinatal transmission ofhepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.
48. Yogeswaran K, Fung SK. Chronic hepatitis B in pregnancy:unique challenges and opportunities. Korean J Hepatol2011;17:1-8 [Epub 2011/04/16].
49. Denis F, Tabaste JL, Ranger-Rogez S. Prévalence de l'AgHBschez environ 21 500 femmes enceintes. Enquête dans 12centres hospitaliers français. Pathol Biol (Paris) 1994;42:533-8.
50. Blondel BDMC, Breart G. Enquête nationale périnatale 1995. Rapport de fin d'étude. Unité de recherche épidémiologiquesur la santé des femmes et des enfants Inserm U149; 1995.